安神止痒健脾方对儿童特应性皮炎的疗效及生活质量改善的临床研究

注册号:

Registration number:

ITMCTR2100004594

最近更新日期:

Date of Last Refreshed on:

2021-01-01

注册时间:

Date of Registration:

2021-01-01

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

安神止痒健脾方对儿童特应性皮炎的疗效及生活质量改善的临床研究

Public title:

Clinical study of Anshenjianpizhiyang granule's curative effect and improvement degree of life quality to children with atopic dermatitis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

安神止痒健脾方对儿童特应性皮炎的疗效及生活质量改善的临床研究

Scientific title:

Clinical study of Anshenjianpizhiyang granule's curative effect and improvement degree of life quality to children with atopic dermatitis

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100041591 ; ChiMCTR2100004594

申请注册联系人:

马梦茜

研究负责人:

郎娜

Applicant:

Ma Mengxi

Study leader:

Lang Na

申请注册联系人电话:

Applicant telephone:

+86 13126826030

研究负责人电话:

Study leader's telephone:

+86 13661140663

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

mamengxi1997@163.com

研究负责人电子邮件:

Study leader's E-mail:

langna96@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区中直路西苑操场1号

研究负责人通讯地址:

北京市海淀区中直路西苑操场1号

Applicant address:

1 Xiyuan Playground, Zhongzhi Road, Haidian District, Beijing, China

Study leader's address:

1 Xiyuan playground, Zhongzhi Road, Haidian District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院西苑医院

Applicant's institution:

Xiyuan Hospital of Chinese Academy of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2020XLA031-2

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

中国中医科学院西苑医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Xiyuan Hospital of Chinese Academy of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/5/19 0:00:00

伦理委员会联系人:

訾明杰

Contact Name of the ethic committee:

Zi Mingjie

伦理委员会联系地址:

北京市海淀区中直路西苑操场1号

Contact Address of the ethic committee:

1 XiyuanPplayground, Zhongzhi Road, Haidian District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国中医科学院西苑医院

Primary sponsor:

Xiyuan Hospital of Chinese Academy of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

北京市海淀区西苑操场1号

Primary sponsor's address:

1 Xiyuan playground, Zhongzhi Road, Haidian District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院西苑医院

具体地址:

海淀区西苑操场1号

Institution
hospital:

Xiyuan Hospital of Chinese Academy of traditional Chinese Medicine

Address:

1 Xiyuan Playground, Zhongzhi Road, Haidian District

经费或物资来源:

首都卫生发展科研专项

Source(s) of funding:

Capital health development research project

研究疾病:

特应性皮炎

研究疾病代码:

Target disease:

Atopic dermatitis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

1.观察安神止痒健脾方干预轻、中度特应性皮炎儿童治疗前后病情严重程度,以及生活质量改善的变化。 2.通过采用ELISA方法,蛋白质及代谢组学技术,阐明安神止痒健脾方干预轻、中度特应性皮炎的机制。

Objectives of Study:

1. Observe the severity and changes in quality of life improvement of children with atopic dermatitis using Anshenjianpizhiyang granule before and after treatment. 2. Clarify the Anshenjianpizhiyang granule's mechanism to intervene the mild and moderate atopic dermatitis by ELISA method,protein and metabonomics technology.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1、符合特应性皮炎中、西医诊断标准; 2、证候选择参照以上《中医病证诊断疗效标准》中四弯风诊断标准; 3、评分为轻、中度患儿; 4、年龄在 6-12 岁儿童; 5、监护人签署知情同意书且依从性好。

Inclusion criteria

1. Patients with atopic dermatitis in accordance with the diagnostic criteria of Chinese and Western medicine; 2. The patients whose syndromes refer to the four bend wind diagnostic criteria in the above "diagnostic and therapeutic criteria of TCM diseases and syndromes" were selected; 3. Children with mild to moderate scores; 4. Children aged 6-12 years old; 5. Children have good compliance and guardians sign informed consent.

排除标准:

1、一周内曾口服抗组胺类药物; 2、外用糖皮质激素或者钙调磷酸酶抑制剂者; 3、肝肾功能异常或患有严重系统性疾病、先天性疾病者、免疫性疾病者; 4、合并其他皮肤病,细菌(真菌)感染等;合并胃肠道疾病(肠炎、菌痢 等); 5、对治疗药物过敏者; 6、同时参加其他临床试验的儿童。

Exclusion criteria:

1. Children who have taken antihistamine drug in one week. 2. Patients with topical corticosteroids or calcineurin inhibitors. 3. Children with liver and kidney dysfunction,serious systemic diseases,congenital diseases,immune diseases. 4. Children with other skin diseases, bacterial (fungal) infection,gastrointestinal diseases(enteritis, bacillary dysentery, etc). 5. Patients allergic to therapeutic drugs. 6. Children who attand in other clinical trails at the same time.

研究实施时间:

Study execute time:

From 2021-03-01

To      2023-06-01

征募观察对象时间:

Recruiting time:

From 2021-03-01

To      2023-06-01

干预措施:

Interventions:

组别:

对照组

样本量:

30

Group:

control group

Sample size:

干预措施:

安慰剂

干预措施代码:

Intervention:

placebo

Intervention code:

组别:

治疗组

样本量:

30

Group:

treatment group

Sample size:

干预措施:

安神健脾止痒方

干预措施代码:

Intervention:

Anshenjianpizhiyang granule

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院西苑医院

单位级别:

三级甲等

Institution/hospital:

Xiyuan Hospital of Chinese Academy of traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

炎症指标

指标类型:

次要指标

Outcome:

Inflammatory indicators

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

组织学指标

指标类型:

次要指标

Outcome:

Histological index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

认知功能

指标类型:

次要指标

Outcome:

cognitive function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量

指标类型:

主要指标

Outcome:

Quality of life

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SCPRAD评分

指标类型:

主要指标

Outcome:

SCPRAD score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 6
Min age years
最大 12
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机化方案是由西苑医院GCP中心的一名统计员编制的。参与者将被以1:1的比例随机分配到治疗组或安慰剂组,一共分为4个固定块。使用密封不透明信封进行随机化隐藏,随机化序列号和分组分配信息将密封在有序信封中。随着病人的加入,这些信封将依次打开,信封将由不参与治疗或评估的研究助理保管。

Randomization Procedure (please state who generates the random number sequence and by what method):

The randomization scheme has been prepared by a statistician from Xiyuan Hospital GCP Center. Participants will be randomly assigned to the treatment or placebo groups in a 1:1 ratio with the fixed block of 4. Sealed opaque envelopes will be used to ensure randomization concealment.

盲法:

双盲

Blinding:

Double blind

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

具体数据可联系mamengxi1997@163.com进行获取。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Send E-mail to mamengxi1997@163.com for specific data.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究所采集的数据和临床资料数据使用病例记录表记录,采用Epidate软件进行双录入。录入结束后, 对两次录入的数据库通过软件进行双份数据的核对和逻辑一致性校验。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data and clinical data collected in this study will be recorded by Case Record Form,and use Epidate software for double input.After entering,double data check and logical consistency verification will be carried out for the two entered databases through software.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统